New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.

In comparison to systematic biopsy, researchers found that mpMRI-targeted biopsy had a nine percent higher detection rate for cribriform and intraductal prostate cancer subtypes that are associated with adverse outcomes.

While a variety of factors can influence key decisions such as career moves, conservative projections of absolutes can help reduce the risk of unwelcome surprises.

Catch up on the top radiology content of the past week.

Emerging research suggests CT radiation dosing of 50 mSv or greater is associated with higher mortality at two years but nearly half of those patients were alive 10 years later.

While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.

The ninth FDA clearance for the Swoop Portable MR Imaging system is for new software that enables significant scan time reduction for brain MRI scans.

After being informed about the benefits and risks associated with screening mammography, over a third of women polled indicated a preference to delay breast cancer screening.

The deep learning SubtleSynth software creates synthetic STIR images that are reportedly interchangeable with conventional sequences obtained from T1 and T2-weighted MRI.

The Aperto Lucent open 0.4T MRI platform reportedly offers enhanced fat suppression and spatial resolution capabilities in addition to its open architecture design.

Researchers found that mpMRI was 18 percent more accurate than dual-energy CT (DECT) for T1 staging and 19 percent more accurate for N3 staging of gastric cancer.

Review the case and test your knowledge to make the correct diagnosis.

Offering dedicated PET imaging of the brain, the compact NeuroLF system may facilitate patient comfort while enabling detection and monitoring of brain tumors, epilepsy, and neurodegenerative diseases such as Alzheimer’s disease.

Going into effect in 2015, the Category III CPT add-on code may facilitate broader access to the use of fluorescence imaging for assessing margins after lumpectomies for signs of residual breast cancer.

Emerging research revealed that a machine learning combination of amyloid beta PET and structural MRI demonstrated an 89 percent AUC in differentiating between older healthy patients and those with Alzheimer’s disease.